tm
Seeing Is Believing
tm
Seeing Is Believing
NAMS is currently covered by 8 analysts with an average price target of $47.15. This is a potential upside of $27.97 (145.83%) from yesterday's end of day stock price of $19.18.
NewAmsterdam Pharma Company N.V.'s activity chart (see below) currently has 57 price targets and 49 ratings on display. The stock rating distribution of NAMS is 9.09% HOLD and 90.91% BUY.
Analysts average stock forecasts to be materialized ratio is 39.21% with an average time for these price targets to be met of 214.5 days.
Highest price target for NAMS is $60, Lowest price target is $37, average price target is $47.15.
Most recent stock forecast was given by LEONID TIMASHEV from RBC on 05-Oct-2026. First documented stock forecast 18-Dec-2022.
Currently out of the existing stock ratings of NAMS, 1 are a HOLD (9.09%), 10 are a BUY (90.91%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 30-Oct-2023
$42
$23.1 (122.22%)
$50
1 months 5 days ago
(05-Oct-2026)
7/12 (58.33%)
$19.2 (84.21%)
378
Buy Since 16-Jan-2024
$60
$41.1 (217.46%)
$37
5 months 29 days ago
(12-May-2026)
4/5 (80%)
$21.11 (54.28%)
350
Buy Since 18-Jan-2024
$45
$26.1 (138.10%)
$30
8 months 22 days ago
(19-Feb-2026)
1/2 (50%)
$10.37 (29.95%)
623
Buy Since 12-Jun-2025
$49
$30.1 (159.26%)
$42
8 months 22 days ago
(19-Feb-2026)
0/2 (0%)
$14.37 (41.50%)
Buy Since 28-Aug-2024
$48
$29.1 (153.97%)
$40
8 months 23 days ago
(18-Feb-2026)
7/10 (70%)
$12.24 (34.23%)
285
What is NAMS (NewAmsterdam Pharma Company N.V.) average time for price targets to be met?
Which analyst most recently updated their price target on NAMS (NewAmsterdam Pharma Company N.V.)?
Which analyst has the most public recommendations on NAMS (NewAmsterdam Pharma Company N.V.)?
Which analyst is the currently most bullish on NAMS (NewAmsterdam Pharma Company N.V.)?
Which analyst is the currently most reserved on NAMS (NewAmsterdam Pharma Company N.V.)?
